Day 3Wednesday, 25 March 2026

QPMind is a new kind of biotech company – the first biotech company to apply the combination of AI with Quantitative Systems Pharmacology (QSP), a sophisticated method of biological modeling, to drive the drug discovery process de novo with a platform approach for central nervous system (CNS) diseases. The company was founded in 2023 by experienced entrepreneurs in biotech who know drug discovery, AI for drug discovery and QSP modeling, and who have significant prior work to draw upon for QPMind’s initial platform.

QPMind’s vision is to build an organically growing QSP model base that can be applied to all aspects of drug discovery and development to reduce the cost and increase the success rate of drugs in the clinic by a factor of five. The growing model base combined with AI and experts in the field acts as a “super mind” for drug discovery, delivering an efficiency like no prior approach.

At Cogitars, we're transforming the future of drug development by reimagining how clinical trials are designed, conducted, and optimized. We are pioneers in adaptive clinical trial methodologies and Bayesian designs, bringing cutting-edge statistical solutions to biotech and pharmaceutical companies worldwide. Our mission is to accelerate the journey of life-saving therapies from laboratory to patient by making clinical trials smarter, faster, and more efficient. We specialize in the critical challenges of early phase trials (phase I and II), where traditional approaches fall short. Through innovative trial designs, we help our partners minimize patient risk, reduce costs and make more informed decisions at every stage of development. We don't just provide theoretical frameworks—we deliver practical, implementable solutions that span from technical execution to protocol writing and regulatory negotiations. Our team understands that every compound is unique and that novel drugs need tailored designs to maximise success. Our vision extends beyond individual trials. Through evidence synthesis and strategic biostatistical consulting, we help companies optimally prepare for subsequent development phases, building on accumulated knowledge to strengthen their entire development pipeline. At Cogitars, we believe that better statistics means better medicine. We're not just supporting clinical trials—we're revolutionizing how they're done.

Redwood AI supports small-molecule research and manufacturing through an AI-driven software platform that automates the evaluation of synthetic routes and early chemistry decisions. The system is designed to surface practical considerations that influence how a compound moves from discovery toward development, while allowing human oversight where expert judgment is needed.

The platform generates and compares multiple synthetic possibilities and links them to operational factors that often determine whether a route can succeed in practice. These include material availability, supply-chain reliability, process safety, and compatibility with laboratory or plant equipment. By connecting automated predictions with real-world constraints, the platform helps teams understand the downstream implications of different strategies before committing resources.

Redwood AI originated as a spin-off drawing on work from the University of British Columbia, McMaster University, and Stanford University, combining expertise in synthetic chemistry, applied machine learning, and data engineering. We work with pharmaceutical and biotechnology groups, CDMOs, academic laboratories, and non-profit organizations that require structured chemical analysis without maintaining their own cheminformatics infrastructure.

Engagements typically involve automated comparative evaluation of route options, focused assessments of reaction or impurity risks, and development of prioritization frameworks that integrate into existing client workflows. Our aim is to provide clear, technically grounded outputs that support project decisions, strengthen chemistry processes, and facilitate effective handoffs between discovery, development, and external manufacturing partners.

Biorevert was founded with over 25 years of scientific achievements to be translated into cancer reversion therapies. Based on this, we developed our drug discovery platform that can identify novel targets and their mechanism of actions using AI and computational analysis. Despite huge unmet need, there is no specific solution for treating cancer. We believe that our platform technology can fulfill the unmet needs in new drug development market and will be the absolute solution for cancer patients.

Beat Therapeutics is drug discovery & development company advancing first-in-class targeted therapies that disrupt cancer survival mechanisms at the DNA repair level. By exploiting genomic instability as a selective cancer vulnerability, we aim to:
• Deliver superior efficacy by targeting core DNA repair mechanisms.
• Act upstream to block compensatory repair pathways, providing a strategy to overcome resistance.
• Improve the therapeutic window through selective targeting of tumor-specific dependencies.
• Address the urgent unmet needs of patients with aggressive and treatment-resistant cancers.

Traditional early-stage drug discovery depends on screening chemical libraries, a costly and time-consuming process that explores only a tiny fraction of the astronomically large chemical space. Depending on the therapeutic target, these workflows can take several years and cost millions of dollars. Baio reshapes early-stage drug discovery by exploring the entire chemical space with generative AI, and designs novel drug candidates in a fraction of the time. Baio is an EPFL spin-off founded by PhD students Ilia Igashov and Arne Schneuing, together with Professor Bruno Correia. Over the past years, the team have pioneered the field of generative AI for structure-based drug design and developed a set of tools that have been widely adopted by the community. At Baio, they aim to help pharmaceutical and biotechnology companies accelerate their pre-clinical R&D pipelines.

Founded in 2020 and headquartered in Graz, Austria, myBIOS GmbH is an innovative biotechnology company built on more than 40 years of scientific expertise. The company specializes in the production of high-value recombinant proteins, including alternative proteins, industrial enzymes, and bioactive peptides, serving a broad range of industrial sectors such as pharmaceuticals, food and feed, cosmetics or materials. At myBIOS, our mission is to redefine the future of recombinant protein production through our proprietary methanol-free fermentation technology, utilizing the yeast Pichia pastoris (Komagataella phaffii). This platform, based on non-toxic inducers, establishes new industry standards for safety, sustainability, and cost-efficiency. By achieving high protein titres without the use of methanol, we significantly reduce environmental impact and regulatory complexity, enabling compatibility with non-ATEX-certified facilities and simplifying implementation. This positions our technology as a scalable and accessible solution with the potential to transform protein manufacturing across diverse industries. Through our commitment to delivering affordable, high-quality, and sustainable protein solutions, myBIOS is driving meaningful progress in biotechnology and industrial biomanufacturing.

TaBriX Ltd is a UK-based preclinical biotechnology company developing first-in-class, pathogen-directed immunotherapies designed to shorten treatment duration and reduce relapse in chronic lung infections. Rather than incremental antimicrobial activity, TaBriX addresses a structural failure in current infectious-disease care pathways: the inability of antibiotics alone to clear persistent intracellular pathogens. Current standard of care requires prolonged combination antibiotic regimens lasting 12–24 months, delivers modest efficacy (35–60%), and is associated with relapse rates exceeding 50%. These long treatment cycles drive toxicity, non-adherence, repeat hospitalizations, and escalating system-level costs. TaBriX’s core insight is that treatment duration—not drug potency—is the primary driver of both clinical failure and economic inefficiency in NTM care. TBX-4881, our lead asset, inhibits PtpB, critical in the pathogen's immune-evasion mechanisms to survive in the host. TBX-4881 is designed to restore host innate immune clearance mechanisms, enabling faster and more durable pathogen elimination and increasing efficacy of existing antibiotics.

MgShell was founded to address a structural limitation in the treatment of ocular chronic diseases, starting with age-related macular degeneration, where current therapeutic models are clinically effective but not sustainable in the long term. In retinal diseases, the reliance on frequent intravitreal injections leads to poor patient adherence, high clinical burden, huge significant indirect costs, and very low real-life efficacy. The main limitation lies not in the drug itself, but in the mode of administration.To address these challenges, MgShell is developing a bioresorbable intraocular drug delivery system with programmed drug release, enabling a significant improvement in treatment adherence, a reduction in the number of intravitreal injections, and enhanced real-world efficacy. This solution substantially lowers the risk of irreversible vision loss and reduces therapy-related ancillary costs, while creating new business opportunities for pharmaceutical companies. MgShell's competitive advantage lies in its multidisciplinary team and a drug-independent, biodegradable magnesium platform. The founders combine expertise in ocular drug delivery, magnesium medical devices, and retinal clinical practice, supported by advisors with senior pharma R&D, clinical, CMC, and business backgrounds. The modular carrier enables extended, programmable drug release via standard intravitreal injection, compatible with existing and future therapies, including combinations. The business model is based on strategic partnerships with pharma companies through licensing or co-development, enhancing real-world efficacy and extending product lifecycles.

Sapu Nano and Sapu Bioscience are complementary therapeutics companies built to solve two of the hardest problems in oncology—delivery and biology. Sapu Nano advances a proprietary Deciparticle™ nanomedicine platform that engineers sub-20 nm particles to improve biodistribution and tumor penetration for hard-to-formulate drugs, with its lead program IV Sapu-003 (everolimus) designed to deliver predictable systemic exposure and reduce the limitations seen with oral dosing, supported by an integrated ISO-5 cGMP manufacturing capability for rapid translation from formulation to clinical supply. Sapu Bioscience focuses on precision oncology and immunomodulatory biology, led by OT-101 (trabedersen)—a TGF-β2–targeting antisense designed to reduce tumor immune evasion—while also advancing TGFB2-guided strategies to improve outcomes and tolerability of standard therapies (e.g., taxanes) through biomarker-driven patient selection and optimized treatment approaches.